secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001655759-25-000069
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas reports preclinical combo data for PROTAC BCL6 degrader ARV-393 with complete regressions in lymphoma
--------------------------------------------------------------------------------

- ARV-393 plus R-CHOP induced complete tumor regressions in all mice, outperforming single agents alone.
- Combination with SOC biologics (rituximab, tafasitamab, polatuzumab vedotin) resulted in tumor regressions in DLBCL models.
- ARV-393 increased CD20 expression in preclinical models, supporting combinations with CD20-targeted agents.
- Combination with investigational SMIs (acalabrutinib, venetoclax, tazemetostat) showed superior growth inhibition with regressions.
- Phase 1 study for ARV-393 (NCT06393738) enrolling patients with relapsed/refractory non-Hodgkin lymphoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000069/0001655759-25-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000069/arvn-20250428.htm
  HTML page:      https://secwatch.observer/filing/0001655759-25-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer